Cord Blood Stem Cells FAQs

Cord blood is the excess blood found in the placenta and umbilical cord after your baby is born. It is rich in hematopoietic stem cells (HSCs) that produce blood tissue in the human body.

If not collected at the time of your baby's birth, this precious resource will be discarded as medical waste. Learn more about cord blood.

Stem cells from cord blood are the "building blocks" of our blood and immune systems. They are capable of self-renewal and regeneration and have the amazing ability to repair and rebuild damaged tissue within the body.

80 diseases and conditions are routinely being treated with cord blood stem cells, including leukemia, lymphoma, various anemias and more.

Current research in regenerative medicine has shown successful results in treating diabetes, cerebral palsy, autism, spinal cord injuries and heart disease.

The potential for future treatments using cord blood stem cells appears to be infinite.

It is estimated that as many as 1 in 3 people in the United States may benefit from stem cell regenerative medicine therapy, including treatments for type 1 diabetes, multiple sclerosis, stroke, heart failure, liver damage, Alzheimer’s, and more.¹

¹ Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4:269-274. Epub August 5, 2008.

Yes. Cerebral palsy, autism and many lymphomas, sarcomas and tumors have successfully been treated using a patient's own cord blood stem cells.¹

There are, however, some conditions for which doctors will prefer to use stem cells from a related donor such as a sibling or child. As such, it is recommended that you bank cord blood for each of your children.

¹ Institute of Medicine of the National Academies. (2005). Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program. Washington DC: The National Academies Press.

Yes. Scientists have developed a method to expand the number of stem cells within a cord blood unit before infusing them into adult patients.¹

Expanded cord blood units result in up to a 164-fold increase in the number of hematopoietic stem cells, making one cord blood unit suitable for transplant in an average size adult.

¹ Fred Hutchinson Cancer Research Center (2010, January 18). First successful use of expanded umbilical- cord blood
units to treat leukemia. Science Daily. Retrieved January 20, 2010, from http://www.sciencedaily.com/releases/2010/01/100117150820.htm? utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+ News%29

HLA, or human leukocyte antigens, are the proteins that control tissue compatibility. The closer the match, the less risk of a potentially fatal condition called GVHD, or graft-versus-host disease (also known as "rejection").

There is no risk of GVHD when a child receives his or her own cord blood. Within a family, there is a high probability of cord blood matching a sibling or parent, thereby significantly reducing the risk of GVHD.

Outside of the family, the situation is much different. HLA antigens are highly polymorphic, with hundreds of different HLA antigens found in the human population (roughly 750,000 possible combinations of three HLA antigens alone).¹

Your best chance of providing a match for your family is to bank your baby's own cord blood.

¹ Beatty, P., & Dahlberg, S. (1988). Probability of finding HLA-matched unrelated marrow donors. Transplantation (4), 714-718.

GVHD, or graft-versus-host disease, is the leading cause of death following transplant surgery. Nearly 50% of all patients who develop GVHD will die as a result.¹

GVHD occurs when the healthy cells of the donor tissue attack the immunocompromised cells of the recipient.

The risk of GVHD is directly related to tissue compatibility and the biological relationship of the donor to the recipient, which is described in terms of HLA matching.

Siblings and parents of the child that the stem cells came from will have the greatest chance of a perfect or close HLA match. The closer the HLA match, the lower your risk of GVHD.

¹ eMedicine. (January 6, 2009). Retrieved April 1, 2010 from Graft Versus Host Disease: Mortality/Morbidity: http://emedicine.medscape.com/article/886758-overview.

Yes. The risk and severity of GVHD is much higher with stem cells from bone marrow than it is with stem cells derived from cord blood and cord tissue.

In addition, cells from bone marrow are more likely to have been exposed to latent diseases and DNA degradation.

Yes. Cord blood stem cells are distinctively different from embryonic stem cells.

Cord blood stem cells are collected from the umbilical cord after your baby is born, and if not saved are discarded as medical waste. There are no ethical oppositions to the use of cord blood stem cells.

Embryonic stem cells are derived from a process that inhibits the life of the embryo, which make them highly controversial.

No. After more than three decades and greater than 40,000 cord blood transplants, the use of cord blood stem cells is considered standard therapy in the treatment of more than 80 diseases and conditions.

The field of stem cell therapy is growing rapidly, and the future potential is unlimited.

Current studies are evaluating the effects of using cord blood stem cells to treat diabetes, cerebral palsy, autism, spinal cord injuries, heart disease, and more. Scientists are also using cord blood stem cells to stimulate lung development in premature babies.

Saving your baby's cord blood gives your family the security of being able to take advantage of future advances in stem cell treatments.